date:Feb 04, 2013
s.
BASF will fully integrate Pronova into its Nutrition Health division and Pronova will become a key part of BASFs omega-3-business.
Last week it BASF noted that all regulatory approvals required for completion of the voluntary offer have been obtained.
Pronovas active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range